Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimidex and Weight Loss in Obese Hypogonadal Men
NCT02959853Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2016
- Primary completion
- Nov 2018
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of anastrozole in hypogonadotropic hypogonadism (HH) (2 arms), sponsored by Baylor College of Medicine. Primary endpoints: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion at 6 months and Change in Symptoms Score of Hypogonadism at 6 months. Started Jun 2016; status: completed.
02
Drugs
anastrozole
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on NCT02959853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959853.